---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-037688"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2024-12-17T23:59:59+00:00"
generated_at: "2026-05-29T02:41:02.899388+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BioCardia commercially launches Morph DNA steerable introducer product family

## Summary
- Morph DNA steerable introducer family now commercially available; currently used in ongoing cell-therapy clinical trials.
- CEO Peter Altman says sales pipeline explored organically without a direct sales force or third-party partners.
- Anticipates final results of CardiAMP Heart Failure I trial and active enrollment in CardiAMP Heart Failure II by Q1 2025.
- Company remains focused on its FDA breakthrough-designated cell therapy for ischemic heart failure.

## SEC filing metadata
- accession: 0001437749-24-037688
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2024-12-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774924037688/0001437749-24-037688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774924037688/bcda20241217_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-037688
- JSON: https://secwatch.observer/filing/0001437749-24-037688.json
- Plain text: https://secwatch.observer/filing/0001437749-24-037688.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.